•
Sep 30, 2020

AMN Healthcare Q3 2020 Earnings Report

AMN Healthcare's Q3 2020 financial performance was announced, revealing mixed results due to the ongoing pandemic.

Key Takeaways

AMN Healthcare reported Q3 2020 revenue of $552 million, a 3% decrease year-over-year. While nurse staffing showed strength due to the COVID-19 pandemic, other service lines experienced continued impacts. Net income and adjusted EBITDA both increased by 11% year-over-year.

Third quarter financial results exceeded guidance, driven by strong nurse staffing demand related to the COVID-19 pandemic.

Revenue was $552 million, a 3% decrease compared to the prior year, with organic revenue down 9%.

Demand for nurses and allied professionals reached record high levels, with improving trends in most other service lines.

Net income was $26 million and adjusted EBITDA was $77 million, both up 11% year-over-year.

Total Revenue
$552M
Previous year: $568M
-2.8%
EPS
$0.82
Previous year: $0.81
+1.2%
Gross Profit
$185M
Previous year: $190M
-2.8%
Cash and Equivalents
$58.4M
Previous year: $40.7M
+43.4%
Free Cash Flow
$81.1M
Previous year: $71.7M
+13.1%
Total Assets
$2.34B
Previous year: $1.86B
+26.0%

AMN Healthcare

AMN Healthcare

AMN Healthcare Revenue by Segment

Forward Guidance

The company expects revenue in the fourth quarter of 2020 to be up sequentially but flat to down 2% from prior year.

Positive Outlook

  • Nurse and Allied Solutions segment revenue is expected to be flat to slightly down year over year.
  • Travel nurse staffing revenue is expected to be up at least 15% from prior year, with lower volumes offset by higher rates and hours worked.
  • Allied revenue is expected to be lower than prior year by about 15%.
  • Technology and Workforce Solutions segment revenue is expected to rise approximately 150% compared with prior year due to the acquisitions of Stratus Video and b4health.
  • Gross margin is expected to be between 32.4% and 32.7%.

Challenges Ahead

  • Revenue in the fourth quarter of 2020 is expected to be flat to down 2% from prior year.
  • For the Physician and Leadership Solutions segment, revenue is expected to be down from prior year by 26-28% due to generally stable but weaker demand due to the pandemic.
  • SG&A as percentage of revenue is expected to be approximately 20.5%.
  • Operating margin is expected to be between 7.6% and 8.1%.
  • Adjusted EBITDA margin is expected to be between 13.3% and 13.8%.